ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÑîÁ®Æ½ÍŶÓÕ¹ÏÖÌìÆø×ª±äÓëÉç»á¾­¼ÃÒòËØÅäºÏ¼Ó¾çÈ«Çò¿¹Î¢ÉúÎïÒ©ÎïÄÍÒ©ÐÔ

¸å¼þȪԴ£º£º£º¹«¹²ÎÀÉúѧԺ ±à¼­£º£º£ºÎâÁ¢¼á ÉóºË£º£º£ºËïÒ«±ó¡¢»ÆÑÞ ÔĶÁÁ¿£º£º£º

ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±Âí×ÓÊæ¡¢ÃÏ·²Ü·£©¿ËÈÕ£¬£¬ngµç×ÓÓÎÏ·¹«¹²ÎÀÉúѧԺÑîÁ®Æ½ÍŶӾ­ÓÉÑо¿£¬£¬Õ¹ÏÖÁËÌìÆø×ª±äÓëÉç»á¾­¼ÃÒòËØ·´¿¹Î¢ÉúÎïÒ©ÎïÄÍÒ©ÐÔ£¨antimicrobial resistance£¬£¬AMR£©µÄЭͬÇýÐж¯Ó㬣¬²¢Í¨¹ýÈ«ÇòÊý¾ÝÆÊÎöÓë¶àÇé¾°Ô¤²â£¬£¬ÎªÎ´À´AMR·À¿ØÌṩÁËÕþ²ßÖ¸Òý¡£¡£¡£Ïà¹ØÐ§¹û½ÒÏþÓÚ¹ú¼Ê¶¥¼¶ÆÚ¿¯Nature Medicine¡£¡£¡£

Ñо¿ÍŶÓÍøÂçÁËÀ´×ÔÈ«Çò101¸ö¹ú¼ÒÓйØÌìÏÂÎÀÉú×éÖ¯ÍÆ¼öµÄ¾ßÓй«¹²ÎÀÉúÖ÷ÒªÐÔµÄÁùÖÖÄÍÒ©¾úµÄ4502ÌõAMR¼à²â¼Í¼£¬£¬Éæ¼°Áè¼Ý3200ÍòÖêÊèÉ¢¾úÖ꣬£¬Ê±¼ä¿ç¶È´Ó1999ÄêÖÁ2022Äê¡£¡£¡£Êý¾ÝȪԴ°üÀ¨ResistanceMap¡¢È«Çò¿¹¾úÒ©ÎïÄÍÒ©ÐÔºÍʹÓüà²âϵͳ£¨GLASS£©¡¢Å·ÖÞ¿¹¾úÒ©ÎïÄÍÒ©ÐÔ¼à²âÍøÂ磨EARS-Net£©¡¢ÖÐÑǺÍÅ·ÖÞ¿¹¾úÒ©ÎïÄÍÒ©ÐÔ¼à²âÍøÂ磨CAESAR£©ÒÔ¼°Öйú¿¹¾úÒ©ÎïÄÍÒ©ÐÔ¼à²âϵͳ£¨CARSS£©¡£¡£¡£Ñо¿ÖÜÈ«ÆÊÎöÁËÉç»á¾­¼ÃºÍÇéÐÎÒòËØ¶ÔAMRµÄÓ°Ï죬£¬ÆÀ¹ÀÁË¡°¿¹Î¢ÉúÎïÒ©ÎïʹÓÃïÔÌ­¡±¡¢¡°¿É³ÖÐø¿ªÕ¹½¨Ò顱ÒÔ¼°ÌìÆø×ª±äϹ²ÏíÉç»á¾­¼Ã·¾¶£¨SSPs£©³¡¾°ÏÂAMRµÄ¿ªÕ¹Ç÷ÊÆ¡£¡£¡£

Ñо¿·¢Ã÷£¬£¬×Ô2000ÄêÒÔÀ´£¬£¬ËùÓÐÊÕÈë×é±ðµÄ¹ú¼ÒAMRÊ¢ÐÐÂʾùÓÐËùÉÏÉý£¨0.4% [95%CI: -3.2% - 4.1%]£©£¬£¬µ«¸ßÊÕÈë¹ú¼ÒµÄAMRÊ¢ÐÐÂÊÔöÌíËÙÂʽÏÂý£¨0.3% [95% CI: -0.5% - 3.8%]£©¡£¡£¡£³ý̼ÇàùϩÄÍÒ©Í­Â̼ٵ¥°û¾ú£¨CRPA£©Í⣬£¬ÆäËûËùÓÐÄÍÒ©¾úÊ¢ÐÐÂʾù³ÊÉÏÉýÇ÷ÊÆ£¬£¬ÆäÖÐÈý´úÍ·æßÄÍÒ©´ó³¦°£Ï£¾ú£¨3GCREC£©µÄÔöÌíËÙÂÊ×î¿ì¡£¡£¡£

33B26ED17904F97E2703F13FA9E_FB5D645A_CF25D

²î±ðÊÕÈë¹ú¼Ò·Ö×éAMRµÄת±äÇ÷ÊÆ

Ñо¿Ð§¹û¶ÔÈ«ÇòÓÈÆäÊÇÖеÍÊÕÈë¹ú¼ÒµÄAMRÖÎÀí¾ßÓÐÖ÷ÒªÕþ²ßÆôʾ¡£¡£¡£2024ÄêÁªºÏ¹úAMR¸ß¼¶±ð¾Û»áÉÏ£¬£¬Ìá³öÁ˵½2030ÄêÈ«ÇòAMRÏà¹ØéæÃüÂÊïÔÌ­10%µÄÄ¿µÄ¡£¡£¡£¸ÃÑо¿ÎªÈ«ÇòAMRÖÎÀíÌṩÁËÖ÷ÒªµÄ¿ÆÑ§Ö¤¾Ý£¬£¬²¢½øÒ»²½Ö§³Ö¸÷¹úÖÆ¶©ÇкÏ×ÔÉíÉç»á¾­¼Ã¿ªÕ¹Ë®Æ½µÄÓÐÓøÉÔ¤Õ½ÂÔ¡£¡£¡£ÔÚÌìÆø×ª±äÓëÈ«Çò¿µ½¡ÌôÕ½ÈÕÒæÑÏËàµÄÅä¾°Ï£¬£¬Íƶ¯AMR·À¿ØÄÉÈë¿É³ÖÐø¿ªÕ¹Õ½ÂÔ£¬£¬ÒѳÉΪȫÇòÎÀÉúÕþ²ßµÄÖ÷ҪƫÏò¡£¡£¡£

ÂÛÎÄÁ´½Ó£º£º£ºhttps://doi.org/10.1038/s41591-025-03629-3



¡¾ÍøÕ¾µØÍ¼¡¿